![Johannes Holzmeister](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Johannes Holzmeister currently works at Cardiorentis AG, as Chairman & Chief Executive Officer and DiNAQOR AG, as Chairman & Chief Executive Officer.
Cargos activos de Johannes Holzmeister
Empresas | Cargo | Inicio |
---|---|---|
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Director Ejecutivo | - |
DiNAQOR AG
![]() DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Director Ejecutivo | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
DiNAQOR AG
![]() DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
- Bolsa de valores
- Insiders
- Johannes Holzmeister